Trial Profile
A Pilot Study to Assess the Combination of High-Dose Conformal Radiation Therapy (HDCRT) and Pembrolizumab in Modulating Local and Systemic T-cell Responses in Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- Acronyms UVA-AM-001
- 17 Feb 2020 Status changed from active, no longer recruiting to completed.
- 01 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2017 Planned primary completion date changed from 1 Jan 2021 to 1 Mar 2020.